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As post-mitotic cells with great energy demands, neurons depend upon the 
homeostatic and waste recycling functions provided by autophagy. In 
addition, autophagy also promotes survival during periods of harsh stress and 
targets aggregate-prone proteins associated with neurodegeneration for 
degradation. Despite this, autophagy has also been controversially described 
as a mechanism of programmed cell death. Instances of autophagic cell death 
are typically associated with elevated numbers of cytoplasmic 
autophagosomes, which have been assumed to lead to excessive degradation 
of cellular components. Due to the high activity and reliance on autophagy in 
neurons, these cells may be particularly susceptible to autophagic death. In 
this review, we summarise and assess current evidence in support of 
autophagic cell death in neurons, as well as how autophagy dysregulation 
commonly seen in neurodegeneration can contribute to neuron loss. From 
here, we discuss potential treatment strategies relevant to such cell death 
pathways. 
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Autophagy is an intracellular process of self-eating, which provides homeostatic 
maintenance through the capture and degradation of aggregate-prone proteins and 
dysfunctional organelles. More specifically, autophagy encompasses three separate 
mechanisms- microautophagy, chaperone-mediated autophagy and 
macroautophagy, but only the latter will be discussed in this review, and shall be 
referred to as simply ‘autophagy’ herein[1].  
Briefly, autophagy proceeds through the capture of portions of cytoplasm containing 
target material inside expanding membranes, which finally enclose to form double-
membrane vesicles called autophagosomes. Fully formed autophagosomes are 
shuttled along microtubules to lysosomes, whereupon fusion and degradation 
occurs[2, 3]. This removal and recycling serves as an emergency energy supply 
during starvation, but autophagy has also been linked to a diverse range of other 
protective roles[4-7]. These include the capture of invading pathogens[8], context-
dependent tumour suppressive and tumourogenic qualities[9-12], and the removal of 
toxic aggregate-prone proteins often linked to neurodegeneration[13-15]. From these 
findings, interest in autophagy research has surged over the past decade or so[16]. 
Despite these pro-survival roles, autophagy has also been implicated as a 
mechanism of programmed cell death (PCD)[17-19]. Numerous studies have reported 
instances of dying cells displaying accumulated autophagosomes, which engulf large 
portions of the cell’s cytoplasm and which have been presumed to lead to excessive 
destruction of vital components[20, 21]. However, this notion of ‘autophagic cell death’ 
(ACD) has met with some scepticism, with critics arguing that these accumulations of 
autophagosomes may represent a failed rescue response to a lethal stress, as 
opposed to a direct lethal mechanism in its own right[22-24].  
Neurons have high energy demands, and as post-mitotic cells, quality control and 
homeostasis maintenance is vital[25]. From these traits, one would assume neurons 
to rely heavily on autophagy.  Yet, these cells typically display very few 
autophagosomes, suggesting little autophagic activity. However, impairing lysosomal 
function leads to the accumulation of autophagosomes, revealing that autophagy is 
highly efficient in neurons, with a quick progression from vesicle formation to 
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degradation[26, 27]. Due to this high autophagic flux, it is possible that neurons are 
particularly sensitive to ACD. As pathologies like neurodegeneration are associated 
with a progressive loss of neurons, an appreciation of the diverse mechanisms of 
death in these cells may aid the design of future protective and preventative 
treatments for disease. In this review, after briefly covering the autophagy 
machinery, we will compare the seemingly paradoxical roles autophagy plays in both 
promoting cell survival and death in neurons. From there, we will address the 
implications these have for our understanding of ACD, as well as potential 
applications for neuron therapy. 
 
Regulation of the Autophagy Machinery 
The autophagy machinery is highly conserved. The AuTophaGy-related (Atg) genes 
were first observed in yeast[28, 29], but many of the 30+ members of this group have 
mammalian homologues[30]. The different Atg genes regulate each stage of 
autophagosome formation - from initiation of the process, to the nucleation of the 
target membrane, and finally its subsequent elongation and fusion, forming the 
complete vesicle[31]. Various origins of the membrane have been suggested; with 
sites including the endoplasmic reticulum (ER)[32, 33], plasma membrane[34-36], 
mitochondrial membrane[37] and Golgi apparatus[38] all receiving support as sources.   
Under normal conditions, autophagy proceeds at a relatively low basal rate. Multiple 
regulators of autophagy have been identified, but in mammals the best characterised 
is the mammalian Target of Rapamycin (mTOR), which negates the initiation of 
autophagosome formation. However, upon certain stimuli such as starvation, mTOR 
is inactivated, allowing autophagy to proceed. The initial stages of the process are 
mediated by the un-coordinated 51-like kinase 1 (ULK1) complex, which activates 
the downstream Phosphatidylinositide 3-Kinase (PI3K) Class III complex[39]. Vps34, 
the only mammalian Class III PI3K, catalyses PI(3)P generation, allowing for 
recruitment of additional facilitators of autophagosome nucleation. Recently, PI(5)P 
has been shown to be able to substitute for PI(3)P in this regard, and this lipid is 
particularly important in responses to glucose starvation[40]. Membrane elongation is 
completed through the action of two ubiquitin-like conjugation processes: 1) ATG12-
5; 2) LC3-phosphatidylethanolamine (PE)[41-43]. Although the ATG12-5-16L1 complex 
4	  
	  
dissociates from completed vesicles, the LC3-PE conjugate (LC3-II) remains, making 
it a commonly-used marker of autophagosomes[44]. At the end of the process, 
autophagosomes are shuttled to lysosomes and autophagosome-lysosome fusion 
occurs (Fig 1). Lysosomal enzymes like cathepsins degrade the vesicles and their 
cargo, and permeases release amino acids for recycling[45]. The successful 
progression from autophagosome formation to degradation is referred to as 
‘autophagy flux’.  
 
Autophagy in neuronal survival 
Perhaps the clearest demonstration of the importance of autophagy in survival is that 
complete knockout of several of the Atg genes (such as Atg3, 5, 7, 9 and 16L1) 
results in neonatal lethality in mice[30]. Neuron-specific Atg gene knockouts 
specifically reveal that basal rates of autophagy are required for normal neuronal 
survival[46, 47]. Autophagy is utilised as a protective mechanism in response to 
numerous stresses. As well as during harsh environmental cues such as 
starvation[48, 49] or hypoxia[50], autophagy action can also promote survival through 
the clearance of faulty intracellular material.  For instance, the specialised 
subdivision of autophagy that targets mitochondria, mitophagy, serves as a form of 
quality control for these organelles. Defective mitochondria are targeted by a 
machinery including PTEN-induced kinase 1 (PINK1) and the ubiquitin ligase Parkin, 
which ubiquitinates proteins on their outer membrane, allowing for their selective 
engulfment in autophagosomes. The removal of damaged mitochondria limits the 
risk of further damage from reactive oxygen species (ROS) generation[51-53].  In the 
event of ROS production, autophagy is triggered by upstream activators like AMPK, 
or by increased activity of ATG proteins, again affording protection to cells[53]. In 
some circumstances, autophagy suppresses apoptosis and necrosis[54-57]. Given 
these roles, it is of little surprise that autophagy has emerged as one of the central 
targets in anti-ageing studies. Regimens that enhance the process have led to 
reductions in pathologies that manifest with age across several models[58].  
One of the branches of age-related disease that autophagy has been shown to 
influence is neurodegeneration. A common feature shared across these pathologies 
is the progressive accumulation of toxic aggregate-prone proteins. The identity of the 
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aggregates varies between diseases: Alzheimer’s disease (AD) features amyloid-β 
(Aβ) plaques and intracellular Neurofibrillary Tangles (NFTs) containing Tau 
aggregates[59, 60]; Parkinson’s disease (PD) is characterised by Lewy body inclusions 
that have α-synuclein as a major constituent[61, 62]; and Huntington’s disease (HD) is 
the result of polyglutamine expansions of the huntingtin (Htt) protein[13, 63]. As 
neurons are post-mitotic, ‘in-house’ modes of waste clearance are imperative to 
prevent the formation of these build-ups[25]. Autophagy seems vital in this regard, as 
the narrow entry to the proteasome precludes it handling oligomeric assemblies[15]. 
Therefore, autophagy dysfunction is likely a major contributor to the onset of 
neurodegeneration. Indeed, autophagic activity has been suggested to decrease 
with age in human tissues, including the brain[15, 64, 65]. In some cases, degenerating 
neurons show accumulations of non-degraded autophagosomes in addition to the 
aggregates, implicating a failure of the lysosomal clearance stage in these 
diseases[66-68]. An interesting exception is in the case of HD, where mutant Htt 
appears to reduce the recognition and capture of certain cargoes, as revealed by the 
recently discovered roles that the protein plays in autophagosome-substrate 
interactions[69, 70].  
 
Consistent with these data, knockout of the autophagy regulators Atg5 or Atg7 in the 
mouse CNS results in pathologies comparable to the effects of neurodegeneration, 
including  the presence of protein aggregates coupled with neuronal damage and 
loss[46, 47].  Beclin-1 (mammalian Atg6 homologue) activity decreases in ageing and 
neurodegenerative brains, and similarly, its loss enhances aggregate formation in 
models of AD, PD and HD[64, 71]. Strategies of beclin-1 overexpression complement 
these findings, with enhanced clearance of toxins and reduced neuronal damage[66, 
72]. Mutations commonly associated with neurodegenerative pathologies have also 
been shown to affect autophagy. As examples, mutated Presenilin-1 in AD alters the 
acidification of lysosomes, causing a blockage to autophagosome degradation[73].  
The AD PICALM locus is a well validated hit from genome-wide association studies 
and loss of this protein impairs autophagy and tau clearance and toxicity[74]. In PD, 
defects in Parkin and PINK-1 result in insufficient labelling of damaged mitochondria 
for mitophagy, increasing the risk of ROS generation and further neuron damage[59]. 
Furthermore, α-synuclein accumulation which characterises this disease impairs 
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autophagosome formation[75, 76], and the VPS35 D620N PD mutation has a similar 
impact on the pathway, which impairs autophagy substrate clearance[77]. 
 
Autophagy in cell death 
Are increases in autophagy activity always beneficial for neuronal health? The 
concept of ACD has persisted from the early days of autophagy research, 
representing Class II death in the recently abandoned morphological classifications 
of PCD, alongside apoptosis (Class I), and necrosis (Class III)[23, 78]. Cells 
undergoing ACD are characterised by enhanced numbers of autophagosomes, 
resulting in extensive cytoplasmic vacuolisation[17, 20]. This has largely been 
attributed to increases in autophagosome synthesis and flux, causing excessive 
degradation of important cell components[78]. However, this concept has courted 
controversy across the literature, with some groups proposing these increases in 
autophagic vacuoles are representative of roles more in keeping with autophagy as a 
pro-survival system[22, 24]. Suggestions include autophagy up-regulation as a failing 
salvage effort against lethal stresses, or a clearance system of dying cells, rather 
than a direct route of cell death in and of itself. To try and provide more clarity on this 
issue, various guidelines have been suggested which themselves have attracted 
criticism for being overly stringent[19, 23]. It has been proposed that for an instance of 
cell death to be truly mediated by autophagy, then autophagy ablation by 
pharmacological or genetic inhibitors should provide some protection from lethality. 
In addition, suppression of apoptotic or necrotic processes should provide no such 
alleviation. Several cases of ACD have been strongly supported, such as large 
scale-clearance during development[79-81], and the actions of some chemotherapeutic 
treatments, at least in vitro[21, 82-85]. While a number of studies have supported the 
concept of autophagic cell death, for instance by showing that the death is 
attenuated by loss of autophagic genes[21, 79, 85, 86], the interpretations of such studies 
are not always straightforward. It is possible that one requires some autophagy to 
enable execution of cell death after certain insults, and such experimental paradigms 
using autophagy null states certainly support the concept that autophagy may be 
permissive in these scenarios. However, in order to test if the increased autophagy 
associated with certain forms of cell death is causal, one needs to ideally manipulate 
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autophagy back to normality and not to the null state. As this type of manipulation is 
very challenging, most studies have not excluded the possibility that the increased 
autophagy they observed is not causing the cell death but rather that some 
autophagy is required to execute cell death in a manner analogous to ATP being 
required for apoptosis. The extent of autophagy modulation of cell death may 
depend on cellular contexts and on the duration and strength of autophagy 
induction. Berry and Baehrecke[79] initially observed that both autophagy and 
caspase activity are required for the cell death in salivary glands during Drosophila 
development, and autophagy selectively degrades the caspase inhibitor dBruce to 
induce Drosophila ovary cell death[87]. These studies suggest that multiple possible 
mechanisms may be involved in ACD. In mammalian cells, the role of cellular 
contexts in ACD remains more elusive, whilst autophagy-relevant proteins such as 
beclin-1, Atg7 or DRAM were reported to play a role in cell death in a variety of 
tumour cell lines[88]. 
 
ACD in excitotoxic and ischaemic neuron stress  
Some of the strongest support for ACD as a pathological process has been found 
from conditions of excitotoxicity and hypoxia-ischaemia, stresses that may result 
from traumatic injuries or stroke[89, 90]. Both conditions are potent inducers of 
autophagy, a response presumably associated with damage limitation and survival 
promotion[91]. Some have reported that pharmacological induction of autophagy with 
rapamycin reduces apoptotic and necrotic death during hypoxia, whilst inhibition with 
3-methyladenine (3-MA) and wortmannin enhance this loss[50, 91, 92]. Contrary to this, 
multiple groups have reported that instead this increase in autophagy can contribute 
to lethality.  Using the glutamate receptor activator kainate as a model of 
excitotoxicity results in death in rat cortical neurons which is largely independent of 
apoptotic caspase activation. However, this cell death is reduced by repression of 
autophagosome formation using the PI3K inhibitor 3-MA, or via genetic knockdown 
of Atg7 and beclin-1[93]. These observations have been supported in other excitotoxic 
models[94, 95]. Similar approaches during hypoxia-ischaemia have also aided in 
alleviating neuron loss both in vitro and in vivo. The administration of 3-MA has 
proven neuroprotective in multiple rodent hypoxia-ischaemia models[96, 97], although it 
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is worth bearing in mind that this agent inhibits multiple PI3 kinases and thus has 
many autophagy-independent effects. Interestingly, Atg7 loss in pyramidal neurons 
appears to suppress both caspase-dependent and -independent death, suggesting 
that apoptosis and ACD may both occur in neurons under hypoxia, with autophagy 
serving as a positive mediator of both processes[94]. The distinctive morphological 
changes and increases in autophagic vesicles following hypoxia of rat hippocampal 
neurons has even aided in the coining of a new subtype of ACD, autosis. Autosis 
has been characterised by an increase in both autophagosomes and autolysosomes, 
and displays other unique morphological characteristics, such as a mild extent of 
chromatin condensation and focal swelling of the perinuclear space[86, 98]. Notably, 
autotic death shows an independence from apoptosis and necroptosis, instead 
requiring the activity of the Na+, K+-ATPase. This pump can be blocked with cardiac 
glycosides. Neriifolin belongs to this class of compounds, and reduces cerebral 
infarct size in multiple rodent ischaemic models[99]. Importantly, these improvements 
in neuron survival are coupled with a decline in the number of autophagic vesicles, 
as well as the absence of other autotic features[86]. Therefore, autosis seems to be a 
distinct form of canonical ACD that occurs in neurons. The dependence of this 
phenomenon on the Na+, K+-ATPase may be relevant for the treatment of hypoxia-
ischaemia, as many cardiac glycosides have well characterised safety profiles and 
are widely used in clinical medicine[99].  
So, how can we explain these dramatically opposing results of autophagy activation 
on cell death susceptibility? One possibility is that the extent of autophagy induction 
dictates the outcome. Physiological levels likely still serve a protective role, and 
provide an energy source and relief from oxidative stress. However, over-activation 
may lead to destruction of cellular components, as well as exerting additional strains 
on the neuron through continued autophagosome formation[89, 100] (Fig 2). This form 
of ACD by excessive autophagosome stimulation has also been implicated in the 
neurotoxicity caused by drugs such as MDMA[101]. The involvement of other forms of 
PCD appears to vary under ischaemic stresses, with both caspase-dependent and -
independent cases documented[94, 97]. Whilst neuron type seems an unlikely 
determinant of which scenario takes place (as both have been observed in the same 
population of pyramidal neurons[94]), the neuronal  region or nature of the stress may 
shape the outcome[89]. It is important to consider that to date there is no evidence 
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that specific activation of autophagy induces cell death, and thus it is possible that 
other signalling pathways induced by different neuronal stressors may determine the 
impact of autophagic activity on cell survival.  It has even been postulated that in 
certain circumstances, autophagy may promote apoptosis as a form of damage 
limitation against inflammatory necrosis[91].  
Autophagy-lysosome dysfunction in neurodegenerative disease 
Rather than over-activation of autophagosome synthesis, the combination of 
autophagosome and aggregate accumulations seen in neurodegenerative cells are 
frequently the result of impaired lysosome degradation[63, 102]. Therefore, in such 
instances it seems unlikely that ACD is occurring via excessive degradation of 
cellular components, as there will be impaired autophagic flux. However, these 
accumulations may still have detrimental effects on cell survival. Without a means of 
waste removal, the hallmark toxic aggregates associated with conditions like AD, PD 
and HD can accumulate[59]. Other important homeostatic processes, such as faulty 
organelle removal, will not be fulfilled either in these conditions, which may 
exacerbate damage. Neurotoxins like rotenone and MPTP mimic PD pathology by 
inhibiting complex I of the mitochondrial electron transport chain and causing ROS 
generation[103-105]. Defective mitochondria may disrupt the microtubule-dependent 
trafficking of autophagosomes to lysosomes further, decreasing clearance of 
aggregates and ROS even more[106]. These conditions also favour mitochondrial 
release of cytochrome c to the cytosol, promoting cell death by apoptosis[107]. 
Elevated ROS have a negative impact on lysosomes: decreasing both number and 
their membrane integrity. Lysosomal membrane permeabilisation (LMP) can lead to 
leakage of proteases like cathepsins with damaging consequences[104, 105]. Whilst 
these events can hardly be classified as a bona fide case of ACD, it still highlights 
how impairment of the system can lead to neuron death (Fig 3). Autophagy-
lysosome dysfunction associated death is likely to be of particular relevance to 
conditions like AD and PD, which commonly display defective autophagy flux[15, 59, 
104].  
In such cases, efforts should focus on salvaging lysosomal function and boosting 
autophagy flux. Pharmacological autophagy inducers have been trialled across a 
variety of animal models, and can aid the removal of aggregates associated with AD, 
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PD and HD[59, 108, 109]. In some cases, these treatments provide a degree of cognitive 
restoration[71, 110]. Notably, a number of these therapies have been achieved with 
approved drugs, such as rapamycins[71, 111-114], rilmenidine and spermidine[110, 115].  
A variety of strategies aimed at a number of targets have adopted this concept, with 
some encouraging findings. Agents like the small molecule GTM-1 and natural 
product Arctigenin both enhance autophagic clearance, and are associated with 
reductions in toxic aggregates and improved cognition in AD mouse models[116, 117]. 
Boosting cathepsin activity also provides similar benefits, although the incidence of 
lysosomal membrane permeabilisation in some disease states may make this 
mechanism unfeasible[118]. Glucosylceramide (GlcCer) has been associated with 
reductions in lysosomal activity, and inhibitors of GlcCer appear to provide the 
desired restorative effects for the organelles and improve PD pathology[119, 120]. 
Niemann-Pick Type C (NPC) is another neurodegenerative disease that bears 
similar pathology to AD[121]. In NPC mice, enhancing degradation aids neuron 
survival[122]. An exciting candidate that has emerged in recent years is the 
Transcription Factor EB (TFEB). TFEB is a positive regulator of a number of 
lysosomal and autophagy related genes, with its expression associated with 
enhanced lysosome biogenesis and substrate clearance[123]. As brains of 
neurodegenerative mice models have been reported to show reductions in TFEB, 
the effects of elevating its expression have been investigated[25, 67]. Importantly, 
increased TFEB aids in the degradation of misfolded Tau[124], α-synuclein[67] and 
mutant Htt[25] both in vitro and in vivo. There has been less clear support for Aβ 
plaque removal[124].  Pharmacological autophagy inducers like rapamycin and 
trehalose also activate TFEB, and aid in the clearance of protein aggregates in 
neurodegenerative mouse models, as well as reduce the damage associated with 
neurotoxins like rotenone and MPTP[67, 104, 105]. Table 1 summarises selected 
pharmacological agents/strategies used for autophagy flux restoration in 
neurodegenerative models. 
Concluding Remarks 
The role of autophagy in neuronal survival appears complex. Whilst the homeostatic 
functions of autophagy seem vital for survival through protection against stress and 
the removal of toxins, imbalances in the pathway can promote lethality. Interestingly, 
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it appears that both over-activation and inactivation of autophagy can lead to 
neuronal death. Support for ACD by autophagy over-activation has come from 
observations made during periods of harsh stress like excitotoxicity and hypoxia. In 
these situations, it is possible autophagy acts as an out-of-control protective 
response, and induces death by excess capture and destruction of intracellular 
components. Genetic ablation of the autophagy machinery can alleviate this 
phenomenon.  However, it is important to consider that the experimental paradigms 
that led to the conclusions of autophagic cell death generally use autophagy null 
states or chemical inhibitors like 3-MA or wortmannin which have multiple 
autophagy-independent effects. Thus, autophagy may be permissive for certain 
forms of cell death, but may not be sufficient – we are not aware of any data showing 
that “specific” autophagy hyper-activation by overexpressing a complete ATG gene 
induces cell death. Lysosome dysfunction can also lead to cellular aberrant 
autophagosome accumulation through a block of their degradation, and is 
associated with neurodegenerative pathologies. In such cases there is reduced 
autophagic flux and the failure to successfully clear intracellular protein aggregates 
and ROS means the toxins can propagate unchecked and cause further damage, 
ultimately leading to cellular demise. These differing mechanisms will influence 
treatment strategies. Whilst autophagy inhibitors may improve survival in ACD by 
autophagosome biogenesis over-activation, their application is likely of little use in 
lysosomal dysfunction. For the latter instance, therapies should instead focus on 
restoration of lysosomal function and autophagy flux. Therefore, it is clear that 
targeting autophagy for cell death prevention is not a case of ‘one size fits all’, and 
rather, careful consideration is needed before selecting a treatment strategy. 
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Fig 1. The schematic diagram of autophagy process 
The autophagy process includes autophagosome biogenesis, autophagosome-
lysosome fusion and cargo degradation. The ULK1/2-Atg13-FIP2000 complex, 
negatively regulated by mTOR, senses the signals for autophagosome initiation. The 
class III PI3-kinase complex, containing Vps34, beclin-1/Atg6, p150/Vps15, and 
Atg14, generates PI3P required for autophagosome nucleation. Autophagosome 
elongation involves two ubiquitin-like (UBL) conjugations: the conjugation of the UBL 
protein Atg12 to Atg5, and the conjugation of the UBL protein LC3 to 
phosphatidylethanolamine (PE). Atg5-Atg12 conjugation is catalysed sequentially by 
E1-like enzyme Atg7 and E2-like enzyme Atg10. The Atg5-Arg12 complex then form 
a larger complex with Atg16 and the site of Atg16 recruitment is enabled by its 
binding to WIPI2, which, in turn is recruited to membranes enriched in PI3P or PI5P. 
The Atg5-12 conjugate (Atg5-12) is an E3 ligase that catalyses LC3-PE (LC3-II) 
conjugation that also requires E1-like Atg7 and E2-like Atg3. LC3-II, the lipidated 
from of LC3, is required for the expansion and completion of pre-autophagosomal 
membranes.  
 
Fig 2. One hypothetical model where the extent of autophagy dictates the fate 
of neurons under stress 
When faced with a harsh stress, neurons rely on autophagy induction as a means of 
protection and damage limitation, suppressing cell death and promoting survival. 
This means an inefficient or inhibited level of autophagy can be detrimental for 
neuron health. On the other end of the spectrum, an excessive autophagic response 
may result in degradation of vital cellular components, culminating in autophagic cell 
death (ACD). Therefore, it seems in order for autophagy to exert its protective 
effects, a balance needs to be maintained to avoid neuron death. 
 
Fig 3. Dysfunctional lysosomal clearance of autophagy promotes the 
accumulation of toxic aggregates associated with neurodegeneration 
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Efficient autophagic clearance is required to remove potentially toxic aggregate-
prone proteins in neurons. In instances of lysosomal dysfunction, these 
accumulations can form, and, coupled with the loss of protective autophagy, 
generate further damage to neurons. Ultimately, these stresses can equate to 
neuron loss and neurodegeneration. Strategies of restoring lysosome integrity and 
function allow autophagy degradation to resume, and may provide a means of 







Table 1: Selected strategies of autophagy flux restoration in neurodegenerative 
models (mammalian where available) 
	  
Strategy  Neurodegenerative 
Disease 







































































Niemann-Pick Type-C 1 
 
Autophagy induction; reductions in 
Aβ and cognitive recovery in AD 
mice 
 
Reductions in Htt aggregate 
formation, improvements in 
behavioural tests in mice 
 
Reductions in α-synuclein 
accumulations, alleviations to 
neurodegenerative behaviour in 
mice 
 
Autophagy induction; enhanced 
clearance of mutant Htt, improved 
motor performance in mice 
 
Autophagy induction; Improved 
motor performance in fruit fly, 
Reduced dopaminergic neuron 
loss in nematodes 
 
Autophagy induction; Reduction in 
Aβ plaques through inhibition of 
formation and enhanced 
clearance, improved memory in 
mice 
 
Autophagy induction and 
increased flux; Removal of Aβ 
oligomers, cognitive 
improvements in mice 
 
Corrections to autophagy flux;              
Improved clearance of cholesterol 
and autophagic vesicles in mouse 











































Upregulation of lysosomal and 
autophagy genes; Enhanced 
clearance of Tau, α-synuclein and 
mutant Htt aggregates 
[124] 
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